Antonello Pinto

Dipartimento di Ematologia, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, UOC di Ematologia Oncologica e Trapianto di Cellule Staminali, Napoli, Italy.

View Article and Find Full Text PDF

January 2016

A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma.

Authors:

Stefano Luminari Maria Goldaniga Marina Cesaretti Lorella Orsucci Alessandra Tucci Alessandro Pulsoni Flavia Salvi Luca Arcaini Angelo Michele Carella Alessandra Tedeschi Antonello Pinto Caterina Stelitano Luca Baldini

Leuk Lymphoma 2016 8;57(4):880-7. Epub 2016 Feb 8.

b Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena , Milano , Italy ;

View Article and Find Full Text PDF

December 2016

Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma: reply to D'Arco et al.

Authors:

Antonello Pinto Gaetano Corazzelli

Br J Haematol 2015 Nov 19;171(4):665-8. Epub 2015 Apr 19.

Haematology-Oncology and Stem Cell Transplantation Unit, Department of Haematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy.

View Article and Find Full Text PDF

November 2015

Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents.

Authors:

Antonello Pinto Paolo Corradini Alberto Mussetti Pier Luigi Zinzani

Leuk Lymphoma 2015 Jul 4;56(7):1969-74. Epub 2014 Dec 4.

Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, Fondazione "G. Pascale", IRCCS , Napoli , Italy.

View Article and Find Full Text PDF

July 2015

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

N Engl J Med 2014 Sep;371(10):906-17

The authors' affiliations are listed in the Appendix.

View Article and Find Full Text PDF

September 2014

A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.

Authors:

Filippo Russo Gaetano Corazzelli Ferdinando Frigeri Gaetana Capobianco Luigi Aloj Francesco Volzone Annarosaria De Chiara Annamaria Bonelli Tindaro Gatani Gianpaolo Marcacci Daniela Donnarumma Cristina Becchimanzi Elisabetta de Lutio Franco Ionna Rosaria De Filippi Secondo Lastoria Antonello Pinto

Br J Haematol 2014 Jul 27;166(1):118-29. Epub 2014 Mar 27.

Haematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy.

View Article and Find Full Text PDF

July 2014

The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.

Authors:

Pier Luigi Zinzani Massimo Federico Stefano Oliva Antonello Pinto Luigi Rigacci Giorgina Specchia Alessandra Tucci Umberto Vitolo

Leuk Lymphoma 2015 Jan 24;56(1):12-25. Epub 2014 Mar 24.

Institute of Hematology and Medical Oncology "L. e A. Seràgnoli", University of Bologna , Italy.

View Article and Find Full Text PDF

January 2015

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.

Blood 2013 Nov 1;122(23):3759-66. Epub 2013 Oct 1.

Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy;

View Article and Find Full Text PDF

November 2013

Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.

J Clin Oncol 2013 Sep 19;31(27):3351-9. Epub 2013 Aug 19.

Umberto Vitolo, Marco Ladetto, Carola Boccomini, Barbara Botto, Annalisa Chiappella, Andrea Evangelista, Chiara Lobetti-Bodoni, and Giovannino Ciccone, Città della Salute e della Scienza Hospital and University, Turin; Luca Baldini, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Università di Milano, Milan; Federico De Angelis, Sapienza University, Rome; Alessandra Tucci and Giuseppe Rossi, Spedali Civili Hospital and University, Brescia; Annalisa Chiarenza, Ferrarotto Hospital, Catania; Antonello Pinto, National Institute for Study and Cure of Tumors, Pascale Foundation; Amalia De Renzo, Federico II University, Napoli; Francesco Zaja, Santa Maria della Misericordia Hospital and University, Udine; Claudia Castellino, Santa Croce and Carle Hospital, Cuneo; Alessia Bari, University of Modena and Reggio Emilia, Modena; Isabel Alvarez De Celis, Arcispedale Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia; Guido Parvis, San Luigi Gonzaga Hospital and University, Orbassano; and Enrica Gamba, Roche Italia, Monza, Italy.

View Article and Find Full Text PDF

September 2013